Jeff Jones
Stock Analyst at Oppenheimer
(1.00)
# 3,827
Out of 4,966 analysts
97
Total ratings
26.44%
Success rate
-13.27%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Outperform | $50 | $23.76 | +110.42% | 1 | Sep 2, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $3.20 | +681.25% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $9.64 | +449.79% | 10 | Aug 6, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $56 → $53 | $41.14 | +28.83% | 5 | Jun 27, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $19.97 | +120.33% | 3 | Jun 24, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $20 → $15 | $8.57 | +75.03% | 3 | May 29, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $4.73 | +428.54% | 2 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $2.04 | +733.29% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $5.94 | +186.20% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $32.94 | +161.08% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $9.54 | +88.68% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.77 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $3.41 | +369.21% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $2.44 | +269.61% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.61 | +2,703.74% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $19.72 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.11 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28,800 | $7.95 | +362,164.15% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.20 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.42 | +960.07% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.38 | +19,636.84% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $2.74 | +40,044.52% | 2 | Nov 17, 2022 |
Pelthos Therapeutics
Sep 2, 2025
Initiates: Outperform
Price Target: $50
Current: $23.76
Upside: +110.42%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $3.20
Upside: +681.25%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $9.64
Upside: +449.79%
Kymera Therapeutics
Jun 27, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $41.14
Upside: +28.83%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $19.97
Upside: +120.33%
Y-mAbs Therapeutics
May 29, 2025
Maintains: Outperform
Price Target: $20 → $15
Current: $8.57
Upside: +75.03%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $4.73
Upside: +428.54%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $2.04
Upside: +733.29%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $5.94
Upside: +186.20%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $32.94
Upside: +161.08%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $9.54
Upside: +88.68%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $4.77
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.41
Upside: +369.21%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $2.44
Upside: +269.61%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.61
Upside: +2,703.74%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $19.72
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.11
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $28,800
Current: $7.95
Upside: +362,164.15%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $4.20
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.42
Upside: +960.07%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.38
Upside: +19,636.84%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $2.74
Upside: +40,044.52%